 PALO ALTO, Calif., Feb. 05, 2021 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. Nasdaq: BBIO, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 1, 2021, the compensation committee of BridgeBios board of directors granted 11 new employees restricted stock units for an aggregate of 16,772 shares of the Companys common stock. All of the above-described awards were made under BridgeBios 2019 Inducement Equity Plan the Plan. 